Pitavastatin: Clinical effects from the LIVES Study

Atherosclerosis Supplements

Volumn 12, Issue 3, 2011, Pages 285-288

  Teramoto, Tamio ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CV risk; HDL; Hypercholesterolemia; LIVES; Pitavastatin

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; TRIACYLGLYCEROL;

AGING; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; JAPANESE; LIPID BLOOD LEVEL; LONG TERM CARE; MULTIVARIATE ANALYSIS; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; PREDICTOR VARIABLE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK REDUCTION; SEX DIFFERENCE; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS, PHASE IV AS TOPIC; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JAPAN; KIDNEY DISEASES; MULTICENTER STUDIES AS TOPIC; MUSCULAR DISEASES; PROSPECTIVE STUDIES; PYRROLES; QUINOLINES; RISK; SIMVASTATIN; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 82955205859     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/S1567-5688(11)70888-1     Document Type: Article

References (20)

1. Ose L, Budinski D, Hounslow N, et al. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin 2009, 25:2755-2764.
2. Budinski D, Arneson V, Hounslow N, et al. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol 2009, 4:291-302.
3. Stender S, Hounslow N Robust efficacy of pitavastatin and comparable safety to pravastatin. Atheroscler Suppl 2009, 10:P770.
4. Ose L, Budinski D, Hounslow N, et al. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis 2010, 210:202-208.
5. Hounslow NJ, Budinski D, Eriksson M Pitavastatin 4 mg shows comparable LDL-cholesterol and superior triglyceride reduction to simvastatin 40 mg in high-risk primary hypercholesterolemia or combined dyslipidaemia. Atheroscler Suppl 2010, 11(2):188. (abstract MS389).
6. Saito Y Pitavastatin: An overview. Atheroscl Suppl 2011, 12(3):271-276.
7. Chapman MX Pitavastatin: Novel effects on lipid parameters. Atheroscl Suppl 2011, 12(3):277-284.
8. Foody JM, Mendys PM, Liu LZ, et al. The utility of observational studies in clinical decision making: lessons learned from statin trials. Postgrad Med 2010, 122:222-229.
9. Kurihara Y, Douzono T, Kawakita K, et al. A large-scale, long-term prospective post-marketing surveillance of pitavastatin (Livalo) - Livalo effectiveness and safety study (LIVES). Jpn Pharmacol Ther 2008, 36:709-731.
10. Teramoto T, Urashima M, Shimano H, et al. A large-scale study on cardio-cerebrovascular events during pitavastatin (LIVALO tablet) therapy in Japanese patients with hypercholesterolemia: LIVES 5-year extension study. Jpn Pharmacol Ther 2011, 39:789-803.
11. Teramoto T, Sasaki J, Ueshima H, et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007, 14:45-50.
12. Teramoto T, Kashiwagi A, Mabuchi H Status of lipid-lowering therapy prescribed based on recommendations in the 2002 report of the Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Hyperlipidemia. Curr Ther Res 2005, 66:80-95.
13. Teramoto T, Shimano H, Yokote K, et al. Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. J Atheroscler Thromb 2009, 16:654-661.
14. Sviridov D, Nestel P, Watts G Statins and metabolism of high density lipoprotein. Cardiovasc Hematol Agents Med Chem 2007, 5:215-221.
15. Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006, 97:61C-68C.
16. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
17. Kimura K, Shimano H, Yokote K, et al. Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study. J Atheroscler Thromb 2010, 17:601-609.
18. Grover SA, Kaouache M, Joseph L, et al. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. Arch Intern Med 2009, 169:1775-1780.
19. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301-1310.
20. Barter P HDL-C: Role as a risk modifier. Atheroscl Suppl 2011, 12(3):267-270.